文献速递支持与姑息治疗

免疫治疗时代肿瘤患者皮质类固醇的管理策略

How to manage patients with corticosteroids in oncology in the era of immunotherapy?
PubMed 文献 · Eur J Cancer · 2020-11-16

皮质类固醇在肿瘤科应用广泛,涵盖难治症状、抗肿瘤、支持治疗及免疫相关不良事件等。临床前研究提示其免疫抑制可能削弱免疫治疗活性,但前瞻性研究显示皮质类固醇使用是转移性肿瘤预后的标志物,并未显著改变患者对免疫治疗的反应本身。本文综述了皮质类固醇在肿瘤学中的应用现状及其对免疫治疗活性的潜在影响。

要点

  • 皮质类固醇在肿瘤急症中常作为一线治疗,因其起效快且作用广泛。
  • 临床前研究提示皮质类固醇的免疫抑制可能减弱免疫治疗活性。
  • 前瞻性研究显示皮质类固醇使用是转移性肿瘤预后的标志物,但不显著改变免疫治疗反应。

核心结论

  • 皮质类固醇使用是转移性肿瘤预后的标志物,但并未显著改变患者对免疫治疗的反应本身。

研究设计与样本

  • 本文为综述,回顾了肿瘤学中皮质类固醇使用的现状,重点关注其对免疫治疗活性的潜在影响。

主要发现

  • 临床前研究提示皮质类固醇诱导的免疫抑制可能削弱免疫治疗活性。
  • 前瞻性临床研究显示皮质类固醇使用是转移性肿瘤预后的标志物,但不显著改变免疫治疗反应。

临床怎么用

  • 在免疫治疗时代,需综合评估皮质类固醇的使用指征及其对免疫治疗活性的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Corticosteroids are among the most prescribed drugs in oncology. The indications range from cancer-related indications for refractory symptoms, anti-cancer effects mainly in hematology, supportive measures for cancer-specific treatments and more recently immune-related adverse events induced by modern immunotherapies. In oncological emergencies, corticosteroids are common first-line treatments because of their rapid effect and wide variety of actions. In the last 5 years, with the advance of immune checkpoint inhibitors, corticosteroids are becoming routinely used to manage immune-related adverse effects. Preclinical studies suggested that corticosteroid-induced immunosuppression might dampen the activity of immunotherapies. Prospective clinical studies show that corticosteroid use is a prognostic marker for the cancer outcome in metastatic setting but does not significantly alter the patient's response to immunotherapies per se. Here, we review the state of the art on corticosteroid use in oncology, with a focus on the drugs' potential impact on immunotherapy activity. The comprehensive pharmacological characteristics of corticosteroid drugs, clinical indications, modality of administration and associated precautions for use are discussed in this article.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Aldea M, Orillard E, Mansi L, et al. How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer. 2020. PMID: 33212339. doi:10.1016/j.ejca.2020.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。